Human pathology · 2025
Circulating tumour DNA as a prognostic tool for surgically treated pancreatic ductal adenocarcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aaquist Trine, Henriksen Tenna Vesterman, Mariager Jakobsen Lea Lecanda, Fristrup Claus Wilki, Pfeiffer Per, de Stricker Karin, Sparrelid Ernesto, Moro Carlos Fernández, Mortensen Frank, Knudsen Anders Riegels, Hamilton-Dutoit Stephen, Kleeff Jörg, Mortensen Michael Bau, Andersen Claus Lindbjerg, Detlefsen Sönke
Аннотация
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) has a high risk of early recurrence after surgery. We evaluated the utility of circulating tumour DNA (ctDNA) analysed at different time points as a prognostic tool. Secondary aims were prognostic value of ctDNA combined with plasma carbohydrate antigen (CA) 19-9 and prognostic value of peritoneal tumour DNA (ptDNA).
METHODS: A total of 75 patients were included. Plasma samples were obtained preoperatively, 1 month, and 7-9 months after resection. Peritoneal lavage fluid (PLF) was collected preoperatively and 7-9 months after resection. Cell-free DNA (cfDNA) from plasma and ptDNA were analysed using mutation specific digital droplet PCR assays in a tumour-informed apprach. Kaplan-Meier survival curves, univariable, and multivariable Cox proportional hazard models were used to assess overall survival (OS) and recurrence-free survival (RFS).
RESULTS: Preoperatively, detectable ctDNA was an independent risk factor for OS (HR = 1.88, p = 0.047). Detectable ctDNA 7-9 months after surgery was an independent risk factor for RFS (HR = 4.48, p = 0.017). Detectable ctDNA 1 month after surgery showed decreased RFS (HR = 1.98, p = 0.055). Preoperative, 1-month, and 7-9 months postoperative positivity for ctDNA and/or CA 19-9 showed a significantly worse median OS (p = 0.024, p = 0.008, and p = 0.0003). We did not find association of ptDNA with OS or RFS, but ptDNA detection 7-9 months after surgery was associated with peritoneal RFS (p = 0.003).
CONCLUSION: Our data indicate that detectable ctDNA in plasma taken before and 7-9 months after surgery holds independent prognostic value in PDAC. Combination of ctDNA with CA-19-9 may be a particularly strong prognosticator, which should be confirmed in future studies.
METHODS: A total of 75 patients were included. Plasma samples were obtained preoperatively, 1 month, and 7-9 months after resection. Peritoneal lavage fluid (PLF) was collected preoperatively and 7-9 months after resection. Cell-free DNA (cfDNA) from plasma and ptDNA were analysed using mutation specific digital droplet PCR assays in a tumour-informed apprach. Kaplan-Meier survival curves, univariable, and multivariable Cox proportional hazard models were used to assess overall survival (OS) and recurrence-free survival (RFS).
RESULTS: Preoperatively, detectable ctDNA was an independent risk factor for OS (HR = 1.88, p = 0.047). Detectable ctDNA 7-9 months after surgery was an independent risk factor for RFS (HR = 4.48, p = 0.017). Detectable ctDNA 1 month after surgery showed decreased RFS (HR = 1.98, p = 0.055). Preoperative, 1-month, and 7-9 months postoperative positivity for ctDNA and/or CA 19-9 showed a significantly worse median OS (p = 0.024, p = 0.008, and p = 0.0003). We did not find association of ptDNA with OS or RFS, but ptDNA detection 7-9 months after surgery was associated with peritoneal RFS (p = 0.003).
CONCLUSION: Our data indicate that detectable ctDNA in plasma taken before and 7-9 months after surgery holds independent prognostic value in PDAC. Combination of ctDNA with CA-19-9 may be a particularly strong prognosticator, which should be confirmed in future studies.